We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

ARUP Laboratories Selects Bruker's MALDI Biotyper Solution for Microbial Identification by Proteomic Fingerprinting

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute
Bruker Daltonics has announced that ARUP Laboratories has selected and installed the Bruker MALDI Biotyper system as their next-generation microbial identification system. The MALDI Biotyper has obtained the IVD-CE Mark, and is currently for Research Use Only (RUO) outside of the European Union.

The MALDI Biotyper is a MALDI-TOF mass spectrometry based platform for identifying bacteria, yeasts and fungi. Its carefully curated database includes quality-controlled entries of over 3,700 strains from about 2,000 well-characterized microbial species. Starting from a cultured colony, identification is performed by matching the measured protein fingerprint against the proprietary MALDI Biotyper database.

Bruker informs that, including the database search, automatic identification can be performed in minutes. Multiple colonies can be spotted on a single target, and about 30-60 identifications can be performed every hour. The MALDI Biotyper offers rapid time-to-result, high specificity, very low false positive rates, low operational costs, and low technical barriers for new operators.

Bruker has installed over 150 MALDI Biotyper systems worldwide in routine laboratories for microbiology, and the MALDI Biotyper is rapidly becoming a new standard for robust, rapid microbial identification. ARUP plans to use the MALDI Biotyper for microbial identifications currently performed by DNA sequencing, and expects to see improvements in time to result, workflow and consumables costs. ARUP is also investigating the use of the MALDI Biotyper to replace phenotypic methods for identification, and plans to collaborate with Bruker to develop additional tests on the MALDI Biotyper.

Sherrie Perkins, MD, PhD, ARUP's chief medical officer and director of laboratories stated: "We are excited to have access to this new technology. We hope the equipment will improve our microbiology services to clients, and we look forward to a fruitful collaboration with Bruker."

Dr. Gary Kruppa, Vice President for Business Development of Bruker Daltonics said: "We have enjoyed working with ARUP, and we are very pleased they have selected the MALDI Biotyper for use both in their research and their routine microbial identification production facility. We look forward to continuing to work with ARUP on further applications of the MALDI Biotyper."